Merck’s $11 Billion Bio-Techne Bet Could Change Everything!

Merck KGaA has moved quickly under new CEO Kai Beckmann, agreeing to acquire Bio-Techne (NASDAQ:TECH) in an all-cash transaction valued at roughly $11.3 billion to $11.4 billion. The proposed deal, priced at $73 per share, represents a 24% premium to Bio-Techne’s prior closing price and would be Merck’s largest acquisition since its $17 billion purchase of Sigma-Aldrich more than a decade ago. The timing is important: Merck has faced flat sales growth in recent years, its shares remain materially below 2022 levels, and Beckmann has already signaled that acquisitions will be a central lever for growth across the group. Bio-Techne would strengthen Merck’s life-sciences tools franchise with disposable lab supplies, instruments, proteins, reagents, services, and added exposure to cell-culture technologies through Wilson Wolf. The transaction would be funded with cash and new debt, making execution and integration critical.